Does PENTOSTATIN Cause Second primary malignancy? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with PENTOSTATIN (Nipent). This represents 1.1% of all adverse event reports for PENTOSTATIN.
5
Reports of Second primary malignancy with PENTOSTATIN
1.1%
of all PENTOSTATIN reports
2
Deaths
0
Hospitalizations
How Dangerous Is Second primary malignancy From PENTOSTATIN?
Of the 5 reports, 2 (40.0%) resulted in death.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for PENTOSTATIN. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does PENTOSTATIN Cause?
Neutropenia (42)
Drug ineffective (37)
Off label use (32)
Bk virus infection (30)
Anaemia (28)
Dyspnoea (24)
Pyrexia (24)
Thrombocytopenia (24)
Cystitis haemorrhagic (23)
Product use in unapproved indication (23)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which PENTOSTATIN Alternatives Have Lower Second primary malignancy Risk?
PENTOSTATIN vs PENTOXIFYLLINE
PENTOSTATIN vs PERAMIVIR
PENTOSTATIN vs PERAMPANEL
PENTOSTATIN vs PERAZINE
PENTOSTATIN vs PERCOCET